Comparing Outcomes between Liposomal Daunorubicin/Cytarabine (CPX-351) and HMA+Venetoclax As Frontline Therapy in Acute Myeloid LeukemiaJustin Grenet, Pinkal Desai, Akriti Jain et al.|Blood|2021Cited by 20
Ivosidenib leads to durable responses in IDH1 mutated clonal cytopenias of undetermined significance: A phase II decentralized clinical trialKelly L. Bolton, Eytan M. Stein, Matthew Schwede et al.|Blood|2025Cited by 2
Assessing Role of Comorbidities in Treatment Selection for Older Patients with Acute Myeloid LeukemiaJustin Grenet, Pinkal Desai, Akriti Jain et al.|Blood|2024Cited by 1
IDH1/2-mutant clonal hematopoiesis: A novel driver of autoinflammatory diseaseGriffen Mustion, Kelly L. Bolton, Flore Castellan et al.|Blood|2025Cited by 0